Catalent, Inc.
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Techno…
Drug Manufacturers - Specialty & Generic
US, Somerset [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 14.25 | 141.04 | 123.45 | |
| Graham Fair Price | -30.70 | 15.74 | 22.71 | |
| PEG | 256.05 | 0.49 | 0.14 | |
| Price/Book | 28.15 | 2.84 | 2.22 | |
| Price/Cash Flow | -63.56 | -165.53 | 454.29 | |
| Prices/Earnings | -155.98 | -25.40 | -9.92 | |
| Price/Sales | 19.66 | 9.56 | 7.99 | |
| Price/FCF | -63.56 | -165.53 | 454.29 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 27.68 | 0.21 | 0.17 | |
| Operating Margin | -1.30 | -0.02 | -0.02 | |
| ROA | 50.43 | -0.01 | -0.02 | |
| ROE | -0.06 | -0.03 | 49.94 | |
| ROIC | < 0.005 | < 0.005 | -11.53 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 0.01 | -65.18 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.98 | -0.06 | -93.61 | |
| EPS QOQ | 0.71 | 0.51 | -28.11 | |
| FCF QOQ | 1.12 | -4.44 | 297.93 | |
| Revenue QOQ | 0.04 | 0.05 | 14.16 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 81.77 | 82.01 | 0.30 | |
| Days Sales Outstanding (DSO) | 120.06 | 117.82 | -1.86 | |
| Inventory Turnover | 1.10 | 1.10 | -0.29 | |
| Debt/Capitalization | 0.58 | 0.58 | 0.68 | |
| Quick Ratio | 1.54 | 1.56 | 1.14 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Book Value | 20.26 | 19.84 | -2.06 | |
| Cash | 1.26 | 0.89 | -29.26 | |
| Capex | -0.52 | -0.41 | 21.28 | |
| Free Cash Flow | 0.10 | -0.34 | 244.44 | |
| Revenue | 5.63 | 5.90 | 4.88 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad